The 4th Fc-Mediated Function Summit 2024 was held in Boston, MA from April 17-18, and focused on discussions supercharging FcRn, FcγR, and IgG to advance molecular development, clinical utility, and novel therapeutic applications. During the event, industry experts from across the globe gathered to share the latest research in Fc biology insights, including:
Translating Fc Biology Insights to Innovate Drug Design
Fc Receptor Role in IO Drug Development to Transfer in Autoimmunity
Developing Antibody Target Engagement & Fc-Mediated Function
Targeting FcγR - What is the Next Mutation?
Biointron Summary Report:
1. Innovative Drug Design
Understanding Fc biology, effector functions, and inhibitors to discover opportunities to improve antibody therapeutics.
Using Fc Factor 8 to activate NK cells for specific targeting of unwanted B-cells.
Showcase of mouse models expressing human Fc receptors as tools for translational assessment of Fc receptor-targeted therapies.
2. Autoimmunity
Systemic IgA may be exploited for potential novel therapeutics strategies against infectious disease.
Next generation formats like tetravalent bispecific antibodies in the Fc are beneficial for cancer immunotherapy.
The combination of checkpoint blocking and Fc-mediated tumor cell killing can lead to novel cancer therapeutics.
3. Fc-Mediated Functions
Engineered antibody and albumin molecules with tailored binding and transport properties was discussed.
Evaluation of the main Fc silencing mutations, and what specific needs there are is useful for enhancing diesign optimization.
4. Targeting FcγR
Using the potential of Fc gamma receptors to tune antibody-based immunotherapy with tailored FcgR-blockade.
PD-1 agonist antibodies rely on the mediated clustering of FcγRs to trigger their sppresive function.
Thank you to everyone who visited our booth at the 4th Fc-Mediated Function Summit 2024 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
Learn how multivalent and bispecific VHH antibodies are engineered, their advant……
April 2026 activity saw consolidation in the ADC space, continued expansion of n……
Read on for key trends talked about during the conference: Antibody Therapeutics……
Explore VHH antibody humanization strategies, challenges, and validation methods……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



